Onyx Biotec Limited confirmed zero deviation in utilizing ₹25.38 Crore raised through its IPO. Funds were deployed for manufacturing upgrades, loan repayments, and general corporate purposes.
Onyx Biotec Limited submitted an auditor-signed certificate confirming the utilization of Rs. 25.38 Crore in IPO proceeds for the half-year ended September 30, 2025. The funds were utilized for manufacturing unit upgradation, loan repayment, and general corporate purposes, with no reported deviations from the stated objects.
